Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7DD1

Crystal structure of SRPK1 in complex with a peptide inhibitor

Summary for 7DD1
Entry DOI10.2210/pdb7dd1/pdb
DescriptorSRSF protein kinase 1,SRSF protein kinase 1, ARG-GLU-ARG-ALA-ARG-THR-ARG (3 entities in total)
Functional Keywordsrna splicing, kinase inhibitor, peptide drug, transferase
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains2
Total formula weight46270.08
Authors
Li, Q.Y.,Yung, K.W.Y.,Ngo, J.C.K. (deposition date: 2020-10-27, release date: 2021-04-21, Last modification date: 2023-11-29)
Primary citationLi, Q.,Zeng, C.,Liu, H.,Yung, K.W.Y.,Chen, C.,Xie, Q.,Zhang, Y.,Wan, S.W.C.,Mak, B.S.W.,Xia, J.,Xiong, S.,Ngo, J.C.K.
Protein-Protein Interaction Inhibitor of SRPKs Alters the Splicing Isoforms of VEGF and Inhibits Angiogenesis.
Iscience, 24:102423-102423, 2021
Cited by
PubMed Abstract: Serine-arginine (SR) protein kinases (SRPKs) regulate the functions of the SR-rich splicing factors by phosphorylating multiple serines within their C-terminal arginine-serine-rich domains. Dysregulation of these phosphorylation events has been implicated in many diseases, suggesting SRPKs are potential therapeutic targets. In particular, aberrant SRPK1 expression alters the balances of proangiogenic (VEGF) and antiangiogenic (VEGFb) splicing isoforms of the key angiogenesis factor, vascular endothelial growth factor (VEGF), through the phosphorylation of prototypic SR protein SRSF1. Here, we report a protein-protein interaction (PPI) inhibitor of SRPKs, docking blocker of SRPK1 (DBS1), that specifically blocks a conserved substrate docking groove unique to SRPKs. DBS1 is a cell-permeable inhibitor that effectively inhibits the binding and phosphorylation of SRSF1 and subsequently switches VEGF splicing from the proangiogenic to the antiangiogenic isoform. Our findings thus provide a new direction for the development of SRPK inhibitors through targeting a unique PPI site to combat angiogenic diseases.
PubMed: 33997701
DOI: 10.1016/j.isci.2021.102423
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.05 Å)
Structure validation

237735

數據於2025-06-18公開中

PDB statisticsPDBj update infoContact PDBjnumon